Drug Development
Company announces phase II trial programs for internally developed compounds
Published in Obesity and Diabetes Week, September 12th, 2005
XL999 and XL647 are anticancer compounds, currently in late phase I trials, and the company intends to begin a phase II program for each of these compounds before the end of the year. XL784 has completed a single-dose, phase I trial as well as additional toxicology and formulation development in preparation for a phase II program to test its utility in diabetic nephropathy.
Based on the specific targets of each compound, preclinical data, and insights gained during the phase I trials, the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Epidemiology
Prevalence of type 2 diabetes in obese Argentinean children reported - Diabetes Pathogenesis
Beta-cell function across spectrum of glucose tolerance examined - Diabetes Pathogenesis
FFA receptor links hyperinsulinemia and impaired glucose homeostasis - Diabetes Therapy
Insulin pump provides better glycemic control than daily injections - Insulin Resistance
FOXC2 overexpression prevents diet-induced insulin resistance - Adipose Tissue
Site-specific changes in adipose tissues in obesity investigated - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
